SLC25A1 (also known as the mitochondrial citrate carrier, CIC) in cancer and its potential prognostic implications. SLC25A1 plays a central role in cellular metabolism by transporting citrate out of the mitochondria into the cytosol, where it can be used in lipid biosynthesis and energy production.
• SLC25A1 facilitates the transport of citrate from the mitochondria to the cytosol. Once in the cytosol, citrate can be converted into acetyl-CoA, serving as a substrate for lipid synthesis and histone acetylation.
• By linking mitochondrial metabolism with cytosolic biosynthetic pathways, SLC25A1 plays a key role in metabolic reprogramming—a hallmark of cancer.
-In various cancers, including breast, lung, and colorectal cancers, elevated SLC25A1 expression has been associated—with varying degrees of consistency—with metabolic reprogramming that supports tumor growth and survival. As such, high SLC25A1 levels are often considered a marker of aggressive disease and may correlate with poorer prognosis.
(Will delete Record if Target field = "Delete") Home